Quattro Advisors’s Quest Diagnostics DGX Stock Holding History

Quattro Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-143	Closed	-$24.8K	–	175
2025 Q4	$24.8K	Buy	+143	New	+$26K	0.02%	163

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Quattro Advisors's DGX Position: Q1 2026 in Review

Quattro Advisors sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 143 shares — an estimated $24.8K sold.

Quattro Advisors first reported a position in DGX in Q4 2025 and held it in 1 quarter. The position peaked at $24.8K in Q4 2025. 1,069 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Quattro Advisors reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
Quattro Advisors sold 143 Quest Diagnostics shares in Q1 2026, an estimated $24.8K.
Quattro Advisors first reported a position in Quest Diagnostics in Q4 2025 and held it in 1 quarter.
Quattro Advisors's Quest Diagnostics position peaked at $24.8K in Q4 2025.
1,069 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Quattro Advisors's 13F filing for Q1 2026, filed 15 May 2026.